Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04726241 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 183 to 184v40
  2. Re-verified, no change to tracked fieldsv39
  3. Study sites: 182 to 183v38
  4. Re-verified, no change to tracked fieldsv37
  5. Primary and study completion dates: Dec 31, 2028 to Dec 31, 2030v36
Show 34 earlier versionsHide 34 earlier versions
  1. Study sites: 181 to 182v35
  2. Study sites: 180 to 181v34
  3. Site details revised at 3 of 180 sitesv33
  4. Study sites revised (180)v32 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 178 to 180v31
  6. Site details revised at 11 of 178 sitesv30
  7. Primary and study completion dates: Dec 31, 2026 to Dec 31, 2028 Study sites: 177 to 178v29 Show 1 more changeShow less
    • Study sites: 177 to 178
  8. Study sites: 175 to 177v28
  9. Study sites: 174 to 175v27
  10. Study sites: 172 to 174v26
  11. Study sites revised (172)v25 See this version in full on ClinicalTrials.gov ↗
  12. Study sites: 171 to 172v24
  13. Study sites: 169 to 171v23
  14. Primary endpoints: 1 to 2 Eligibility criteria expanded, about 41 words · Study sites revised (169) · Study description expanded, about 4 wordsv22 Show 3 more changesShow less
    • Eligibility criteria expanded, about 41 words
    • Study sites revised (169)
    • Study description expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  15. Site details revised at 12 of 169 sitesv21
  16. Study sites: 168 to 169v20
  17. Site details revised at 4 of 168 sitesv19
  18. Site details revised at 7 of 168 sitesv18
  19. Phase: Phase 2 to Phase 1/2 Study sites: 167 to 168v17 Show 1 more changeShow less
    • Study sites: 167 to 168
  20. Phase: Not applicable to Phase 2 Start date: Nov 30, 2021 to Apr 18, 2022 · Study sites: 157 to 167 · Eligibility criteria expanded, about 37 wordsv16 Show 3 more changesShow less
    • Start date: Nov 30, 2021 to Apr 18, 2022
    • Study sites: 157 to 167
    • Eligibility criteria expanded, about 37 words

    See this version in full on ClinicalTrials.gov ↗

  21. Study sites: 153 to 157v15
  22. Study sites: 149 to 153v14
  23. Study sites: 145 to 149v13
  24. Study sites: 136 to 145v12
  25. Phase: Not specified to Not applicable Study sites: 109 to 136v11 Show 1 more changeShow less
    • Study sites: 109 to 136
  26. Primary and study completion dates: Jan 30, 2026 to Dec 31, 2026 Study sites: 88 to 109v10 Show 1 more changeShow less
    • Study sites: 88 to 109
  27. Study sites: 75 to 88v9
  28. Study sites: 66 to 75v8
  29. Study sites: 56 to 66v7
  30. Study sites: 44 to 56v6
  31. Study sites: 33 to 44v5
  32. Primary endpoints: 2 to 1 Study sites: 22 to 33 · Eligibility criteria expanded, about 41 words · Collaborators reordered · 1 morev4 Show 4 more changesShow less
    • Study sites: 22 to 33
    • Eligibility criteria expanded, about 41 words
    • Collaborators reordered
    • Study title expanded, about 19 words

    See this version in full on ClinicalTrials.gov ↗

  33. Lead sponsor: Children's Oncology Group to PedAL BCU, LLC Trial status: Not Yet Recruiting to Recruiting · Study sites: 0 to 22 · Start date changed from estimate of Dec 29, 2021 to Nov 30, 2021 · 1 morev3 Show 4 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 22
    • Start date changed from estimate of Dec 29, 2021 to Nov 30, 2021
    • Collaborators: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  34. Start date: Aug 29, 2021 to Dec 29, 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
PedAL BCU, LLC
3 trials monitored
See 1 trial at risk
Leukemia
2,566 trials monitored
See 143 trials at risk
Acute Myeloid Leukemia (AML)
1,203 trials monitored
See 65 trials at risk
Acute Lymphoblastic Leukemia (ALL)
885 trials monitored
See 51 trials at risk
and 2 more diseases
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Trial Details
NCT Number NCT04726241
Lead Sponsor PedAL BCU, LLC
Collaborators: Children's Oncology Group, National Cancer Institute (NCI)
Conditions Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Enrollment 960 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov